Story preview
Continue reading on the publisher site for the full article.
Read on publisher →The Motley Fool
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
8
in the last 3 days
First reported
2 days ago
7 outlets since
Countries
7 other outlets reported this story in the last 3 days.
The pharmaceutical giant still looks like a stable long-term investment.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
AbbVie’s ABBV stock has risen 25.4% over the past six months, supported by strong growth from its newer medicines and improving confidence in its post-Humira growth profile. Skyrizi and Rinvoq sales rose 26.3% and 22.2%, respectively, in the first half of 2026, while the neuroscience portfolio also…